A trial looking at lenalidomide after a donor stem cell transplant for myeloma - LenaRIC

This trial is looking at lenalidomide after a stem cell transplant using cells from a donor. It is for people who have myeloma. This trial is supported by Cancer Research UK.

Doctors can treat myeloma with a stem cell transplant using cells from another person (a donor). This is called an allogeneic stem cell transplant. Before having the transplant, you have a combination of chemotherapy and radiotherapy. Doctors can reduce the possible complications of a transplant by giving lower doses of chemotherapy. They call this a reduced intensity conditioning (RIC) transplant.

Lenalidomide is a type of biological therapy. It works mainly by helping the immune system target cancer cells. We know from research that lenalidomide can help people with newly diagnosed myeloma.

The researchers think that lenalidomide may also be useful for people who have a RIC allogeneic stem cell transplant to treat their myeloma.

The aims of this trial are to

• See if having lenalidomide after a reduced intensity conditioning transplant is safe and helps to stop myeloma coming back

• Learn more about the side effects